Human medicines European public assessment report (EPAR): Sprycel, dasatinib, Precursor Cell Lymphoblastic Leukemia-Lymphoma,Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Date of authorisation: 20/11/2006, Revision: 32, Status: Authorised
Case Medical Research2019
Case Medical Research
Related Papers
- → Dasatinib or high‐dose imatinib for chronic‐phase chronic myeloid leukemia resistant to imatinib at a dose of 400 to 600 milligrams daily(2009)211 cited
- → The combination therapy of imatinib and dasatinib achieveslong-term molecular response in two imatinib-resistant anddasatinibintolerant patients with advanced chronic myeloid leukemia(2016)12 cited
- → Dasatinib rapidly induces deep molecular response in chronic-phase chronic myeloid leukemia patients who achieved major molecular response with detectable levels of BCR-ABL1 transcripts by imatinib therapy(2017)4 cited
- → The combination therapy of imatinib and dasatinib achieves longterm molecular response in two imatinib-resistant and dasatinibintolerant patients with advanced chronic myeloid leukemia(2016)3 cited
- Dasatinib Achieves Higher Response Rate Than Imatinib in CML(2012)